Medium-chain fats added to a Mediterranean diet for newly diagnosed mild cognitive impairment
Tests medium-chain fat supplements in a Mediterranean diet for people with mild cognitive impairment.
Key facts
- Who runs it
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 3 Jul 2024
- Planned end
- 3 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mediterranean-type diet with MCT supplementation
- Mediterranean-type food regimen using extra virgin olive oil
- Record updated
- 4 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a new diagnosis of mild cognitive impairment (MCI), a mild decline in memory and thinking. It compares a Mediterranean-type diet with MCT oil supplements to the same diet with extra virgin olive oil.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- Diagnosed MCI, with symptoms that started less than 24 months ago. People must not be malnourished and must eat enough by mouth to cover their energy needs.
- Earlier treatment
- No experimental therapies in the 2 months before joining. People on insulin therapy or on tube feeding (enteral nutrition) cannot join.
- Biomarker or test result
- Glycated hemoglobin must not be above 8% (64 mmol/mol).
Main reasons for not taking part
- Severe swallowing problems, malnutrition, or an eating disorder
- Liver failure (MELD score > 9), poor pancreas function, or very high cholesterol (>300 mg/dl (7.8 mmol/L)) or triglycerides (>400 mg/dl (4.5 mmol/L))
- Heart failure (NYHA III-IV), unstable angina, or a heart or brain event in the last 6 months
- Other neurological or psychiatric disorders, alcohol abuse, or living in a care institution
- Pregnancy or breastfeeding, or allergy to MCT oil or nuts
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Age between 18 and 85 years
- Diagnosis of MCI
- Disease duration of less than 24 months from symptom onset
- Absence of malnutrition (diagnosed according to the NRS 2002 screening test) and with oral intakes sufficient to cover energy requirements (calculated by the Harris-Benedict formula, adjusted for activity factor and pathology)
- Ability to understand and sign informed consent
Who cannot take part
- Patients on insulin therapy
- Participation in experimental therapies in the 2 months prior to enrollment
- Patients with liver failure: MELD score > 9
- Acute inflammatory disease or ongoing or recent (within 30 days) infectious states
- Heart failure (NYHA III-IV), unstable angina, recent (<6 months) acute cardiovascular or cerebrovascular events
- Neurological disorders other than MCI, psychiatric disorders
- Nutrition and eating disorder
- Allergy to MCT oil, nuts
- Patients with glycated hemoglobin > 8%
- Metabolic disorders and/or enzyme disorders, dyslipidemia with total cholesterolemia >300 mg/dl and/or triglyceridemia >400 mg/dl)
- Patients on total or supplemental enteral nutrition
- Severe dysphagia
- Patients with poor beta-cell function (e.g., pancreasectomy, acute and chronic pancreatitis)
- Malnutrition (diagnosed according to the NRS 2002 screening test) and with per os intakes < 60% of energy requirements (calculated using the Harris-Benedict formula, corrected for activity factor and pathology)
- Hypo- and hyperthyroidism not adequately compensated by treatment
- Pregnancy or lactation
- Alcohol abuse
- Institutionalized patients
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.
The 2 groups in the trial
- Mediterranean-type food regimen using extra virgin olive oilExisting treatment, for comparison
Patients with with first diagnosis of MCI referred to the S.C of Neurology and/or Geriatrics and/or Internal Medicine of the SS. Antonio e Biagio e Cesare Arrigo of Alessandria University Hospital, randomized into the control arm
- Mediterranean-type diet with MCT supplementationTreatment being tested
Patients with with first diagnosis of MCI referred to the S.C of Neurology and/or Geriatrics and/or Internal Medicine of the SS. Antonio e Biagio e Cesare Arrigo of Alessandria University Hospital, randomized into the experimental arm
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment: Prospective Randomized Controlled Trial
- Plain-language title
- Medium-chain fats added to a Mediterranean diet for newly diagnosed mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06951932, who can take part
- Record updated
- 4 May 2025